Fig. 3

SFK inhibitors affect phosphorylation in non-metastatic ccRCC cell lines. a Western blots showing the effect of control (C), 10 % Serum (V), 1, 10, 50 or 100 nM dasatinib or saracatinib on SFK (Y⁴¹⁶), FAK (Y⁸⁶¹) and Src kinase in the non-metastatic, 769-P and 786-O and metastatic ACHN cells. b–d Quantification of western blot results for dasatinib (black bars) and saracatinib (grey bars) in (b) 769-P, (c) 786-O and (d) ACHN cells (n = 3-4: * = 0.05, ** = 0.01, *** = 0.001)